Nuclear Medicine Market

Category : Healthcare & Life Sciences Reports | Delivery Format : PDF,PPT | Publisher: Reports and Insights | Pages : 160

To learn more about this report, request a free sample copy

Nuclear Medicine Introduction

Nuclear medicine also known as radiopharmaceutical in which radioactive isotopes are used for the diagnosis and therapy for variety of diseases,  such as cancer, heart diseases, gastrointestinal, endocrine, neurological disorders. Nuclear medicines are non-invasive in nature and contain specialty that includes the usage of radioactive isotopes in the diagnosis and in treatment of various diseases.

The global nuclear medicine market in 2020 is estimated for more than US$ 4.3 Bn and expected to reach a value of US$ 6.3 Bn by 2028 with a significant CAGR of 4.8%.

Nuclear Medicine Market Key Players

Global nuclear medicine market is mainly dominated by:

  • Siemens AG

  • Eckert & Ziegler

  • Lantheus Holdings, Inc.

  • Cardinal Health

  • Bayer AG

  • Bracco Imaging S.P.A.

  • Nordian Inc.

  • Advanced Accelerator Applications

  • Mallinckrodt plc.

In 2017, the Siemens AG is accounted as the most dominating player in the global nuclear medicine market by holding more than 40% of the global nuclear medicine market followed by GE healthcare and Mallinckrodt PLC

Nuclear Medicine Market Segmentation

The global nuclear medicine market is segmented on the basis of application, radioisotope, source, end user, and by region.

On the basis of application segment, the global nuclear medicine market is segmented into:

  • Oncology

  • Cardiology

  • Gastroenterology

  • Neuroendocrinology

  • Neurology

  • Nephrology

  • Others

In 2018, the oncology application segment is accounted to have the largest market share in terms of value and expected to remain to dominate throughout the forecast period (2019-2027).

Nuclear Medicine Market Dynamics

Evolution towards centralized pharmacies, widespread availability of the SPECT and PET scanning machines, the growing interest of investors of conventional pharmaceutical industries in the therapeutic area, increasing incidence of cancer and cardiovascular diseases are some of the factors that will drive the growth of the nuclear medicine market during the forecast period.

There has been a growing interest in the development of tracers for therapeutic indications during recent years. The increasing number of manufacturers and research organizations are focusing on introducing novel therapeutic radiopharmaceuticals in the market. For instance, in March 2016, Isotopen Technologien München (ITM) raised US$ 20.8 million to fund the clinical development of its promising proprietary pipeline of Targeted Radionuclide Therapies. Also, in May 2016, Clarity Pharmaceuticals, an early stage Australian company, was granted US$ 0.7 million by Federal Government’s in order to fast track the Phase IIa clinical trial of Cu-64 SARTATE, a neuroendocrine tumor imaging radiopharmaceutical.

Regional Segmentation Overview

On the basis of region, the global nuclear medicine market is segmented into six regions namely North America, Latin America, Asia Pacific, Europe, Middle East, and Africa. North America nuclear medicine market is expected to be the most dominating market throughout the forecast period. Availability of key players and increasing healthcare expenditure in the region are some of the revenue boosting factors.


To learn more about this report, request a free sample copy


1.    Global Nuclear Medicine Market Report Overview

1.1.    Introduction

1.2.    Report Description

1.3.    Methodology

2.    Global Nuclear Medicine Market Overview

2.1.    Introduction

2.1.1.    Introduction

2.1.2.    Market Taxonomy

2.2.    Executive Summary

2.3.    Global Nuclear Medicine Market Snapshot

2.4.    Global Nuclear Medicine Market Size and Forecast, 2019–2027

2.4.1.    Introduction

2.4.2.    Market Value Forecast and Annual Growth Rate (AGR) Comparison (2019–2027)

2.5.    Global Nuclear Medicine Market Dynamics

2.5.1.    Drivers

2.5.2.    Restraints

2.5.3.    Opportunity

2.5.4.    Trends

2.6.    Key Regulations

2.7.    Porter’s Five Forces Model

3.    Global Nuclear Medicine Market, By Application

3.1.    Introduction

3.1.1.    Annual Growth Rate Comparison, By Application

3.1.2.    BPS Analysis, By Application

3.2.    Market Revenue (US$Mn) Forecast, By Application

3.2.1.    Oncology

3.2.2.    Cardiology

3.2.3.    Gastroenterology

3.2.4.    Neuroendocrinology

3.2.5.    Neurology

3.2.6.    Nephrology

3.2.7.    Others

3.3.     Global Nuclear Medicine Market Attractiveness Index, By Application

4.    Global Nuclear Medicine Market, By Radioisotope

4.1.    Introduction

4.1.1.    Annual Growth Rate Comparison, By Radioisotope

4.1.2.    BPS Analysis, By Radioisotope

4.2.    Market Revenue (US$Mn) Forecast, By Radioisotope

4.2.1.    Tec. 99

4.2.2.    F18

4.2.3.    Iodine 131

4.2.4.    Lutetium 177

4.2.5.    Yttrium 90

4.2.6.    Gallium 68

4.2.7.    Gallium 67

4.2.8.    Rubidium 82

4.2.9.    Iodine 123

4.2.10.    Iodine 125

4.2.11.    Indium 111

4.2.12.    Others 

4.3.     Global Nuclear Medicine Market Attractiveness Index, By Radioisotope

5.    Global Nuclear Medicine Market, By Source

5.1.    Introduction

5.1.1.    Annual Growth Rate Comparison, By Source

5.1.2.    BPS Analysis, By Source

5.2.    Market Revenue (US$Mn) Forecast, By Source

5.2.1.    Cyclotrons

5.2.2.    Nuclear Reactors

5.3.     Global Nuclear Medicine Market Attractiveness Index, By Source

6.    Global Nuclear Medicine Market, By End User

6.1.    Introduction

6.1.1.    Annual Growth Rate Comparison, By End User

6.1.2.    BPS Analysis, By End User

6.2.    Market Revenue (US$Mn) Forecast, By End User

6.2.1.    Hospitals

6.2.2.    Diagnostic Imaging Centers

6.2.3.    Ambulatory Surgical Centers

6.2.4.    Cancer Research Institute 

6.3.     Global Nuclear Medicine Market Attractiveness Index, By End User

7.    Global Nuclear Medicine Market, By Region

7.1.    Introduction

7.1.1.    Annual Growth Rate Comparison, By Region

7.1.2.    BPS Analysis, By Region

7.2.    Market Revenue (US$Mn) Forecast, By Region

7.2.1.    North America

7.2.2.    Latin America

7.2.3.    Europe

7.2.4.    Asia Pacific

7.2.5.    Middle East

7.2.6.    Africa

7.3.    Global Nuclear Medicine Market Attractiveness Index, By Region

8.    North America Nuclear Medicine Market Analysis and Forecast, 2019–2027

8.1.    Introduction

8.1.1.    Annual Growth Rate Comparison, By Country

8.1.2.    BPS Analysis, By Country

8.2.    Market Revenue (US$Mn) Forecast, By Country

8.2.1.    U.S. Nuclear Medicine Market

8.2.2.    Canada Nuclear Medicine Market

8.3.    North America Nuclear Medicine Market, By Application

8.3.1.    Oncology

8.3.2.    Cardiology

8.3.3.    Gastroenterology

8.3.4.    Neuroendocrinology

8.3.5.    Neurology

8.3.6.    Nephrology

8.3.7.    Others

8.4.    North America Nuclear Medicine Market, By Radioisotope

8.4.1.    Tec. 99

8.4.2.    F18

8.4.3.    Iodine 131

8.4.4.    Lutetium 177

8.4.5.    Yttrium 90

8.4.6.    Gallium 68

8.4.7.    Gallium 67

8.4.8.    Rubidium 82

8.4.9.    Iodine 123

8.4.10.    Iodine 125

8.4.11.    Indium 111

8.4.12.    Others 

8.5.    North America Nuclear Medicine Market, By Source

8.5.1.    Cyclotrons

8.5.2.    Nuclear Reactors

8.6.    North America Nuclear Medicine Market, By End User

8.6.1.    Hospitals

8.6.2.    Diagnostic Imaging Centers

8.6.3.    Ambulatory Surgical Centers

8.6.4.    Cancer Research Institute 

8.7.    North America Nuclear Medicine Market Attractiveness Index

8.7.1.    By Country

8.7.2.    By Application

8.7.3.    By Radioisotope

8.7.4.    By Source

8.7.5.    By End User

9.    Latin America Nuclear Medicine Market Analysis and Forecast, 2019–2027

9.1.    Introduction

9.1.1.    Annual Growth Rate Comparison, By Country

9.1.2.    BPS Analysis, By Country

9.2.    Market (US$Mn) Forecast, By Country

9.2.1.    Brazil Nuclear Medicine Market

9.2.2.    Mexico Nuclear Medicine Market

9.2.3.    Argentina Nuclear Medicine Market

9.2.4.    Rest of Latin America Nuclear Medicine Market

9.3.    Latin America Nuclear Medicine Market, By Application

9.3.1.    Oncology

9.3.2.    Cardiology

9.3.3.    Gastroenterology

9.3.4.    Neuroendocrinology

9.3.5.    Neurology

9.3.6.    Nephrology

9.3.7.    Others

9.4.    Latin America Nuclear Medicine Market, By Radioisotope

9.4.1.    Tec. 99

9.4.2.    F18

9.4.3.    Iodine 131

9.4.4.    Lutetium 177

9.4.5.    Yttrium 90

9.4.6.    Gallium 68

9.4.7.    Gallium 67

9.4.8.    Rubidium 82

9.4.9.    Iodine 123

9.4.10.    Iodine 125

9.4.11.    Indium 111

9.4.12.    Others 

9.5.    Latin America Nuclear Medicine Market, By Source

9.5.1.    Cyclotrons

9.5.2.    Nuclear Reactors

9.6.    Latin America Nuclear Medicine Market, By End User

9.6.1.    Hospitals

9.6.2.    Diagnostic Imaging Centers

9.6.3.    Ambulatory Surgical Centers

9.6.4.    Cancer Research Institute 

9.7.    Latin America Nuclear Medicine Market Attractiveness Index

9.7.1.    By Country

9.7.2.    By Application

9.7.3.    By Radioisotope

9.7.4.    By Source

9.7.5.    By End User

10.    Europe Nuclear Medicine Market Analysis and Forecast, 2019–2027

10.1.    Introduction

10.1.1.    Annual Growth Rate Comparison, By Country

10.1.2.    BPS Analysis, By Country

10.2.    Market (US$Mn) Forecast, By Country

10.2.1.    U.K. Nuclear Medicine Market

10.2.2.    Germany Nuclear Medicine Market

10.2.3.    Italy Nuclear Medicine Market

10.2.4.    France Nuclear Medicine Market

10.2.5.    Spain Nuclear Medicine Market

10.2.6.    Russia Nuclear Medicine Market

10.2.7.    Poland Nuclear Medicine Market

10.2.8.    BENELUX Nuclear Medicine Market

10.2.9.    NORDIC Nuclear Medicine Market

10.2.10.    Rest of Europe Nuclear Medicine Market

10.3.    Europe Nuclear Medicine Market, By Application

10.3.1.    Oncology

10.3.2.    Cardiology

10.3.3.    Gastroenterology

10.3.4.    Neuroendocrinology

10.3.5.    Neurology

10.3.6.    Nephrology

10.3.7.    Others

10.4.    Europe Nuclear Medicine Market, By Radioisotope

10.4.1.    Tec. 99

10.4.2.    F18

10.4.3.    Iodine 131

10.4.4.    Lutetium 177

10.4.5.    Yttrium 90

10.4.6.    Gallium 68

10.4.7.    Gallium 67

10.4.8.    Rubidium 82

10.4.9.    Iodine 123

10.4.10.    Iodine 125

10.4.11.    Indium 111

10.4.12.    Others 

10.5.    Europe Nuclear Medicine Market, By Source

10.5.1.    Cyclotrons

10.5.2.    Nuclear Reactors

10.6.    Europe Nuclear Medicine Market, By End User

10.6.1.    Hospitals

10.6.2.    Diagnostic Imaging Centers

10.6.3.    Ambulatory Surgical Centers

10.6.4.    Cancer Research Institute 

10.7.    Europe Nuclear Medicine Market Attractiveness Index

10.7.1.    By Country

10.7.2.    By Application

10.7.3.    By Radioisotope

10.7.4.    By Source

10.7.5.    By End User

11.    Asia Pacific Nuclear Medicine Market Analysis and Forecast, 2019–2027

11.1.    Introduction

11.1.1.    Annual Growth Rate Comparison, By Country

11.1.2.    BPS Analysis, By Country

11.2.    Market (US$Mn) Forecast, By Country

11.2.1.    China Nuclear Medicine Market

11.2.2.    India Nuclear Medicine Market

11.2.3.    Japan Nuclear Medicine Market

11.2.4.    Australia and New Zealand Nuclear Medicine Market

11.2.5.    South Korea Nuclear Medicine Market

11.2.6.    ASEAN Nuclear Medicine Market

11.2.7.    Rest of Asia Pacific Nuclear Medicine Market

11.3.    Asia Pacific Nuclear Medicine Market, By Application

11.3.1.    Oncology

11.3.2.    Cardiology

11.3.3.    Gastroenterology

11.3.4.    Neuroendocrinology

11.3.5.    Neurology

11.3.6.    Nephrology

11.3.7.    Others

11.4.    Asia Pacific Nuclear Medicine Market, By Radioisotope

11.4.1.    Tec. 99

11.4.2.    F18

11.4.3.    Iodine 131

11.4.4.    Lutetium 177

11.4.5.    Yttrium 90

11.4.6.    Gallium 68

11.4.7.    Gallium 67

11.4.8.    Rubidium 82

11.4.9.    Iodine 123

11.4.10.    Iodine 125

11.4.11.    Indium 111

11.4.12.    Others 

11.5.    Asia Pacific Nuclear Medicine Market, By Source

11.5.1.    Cyclotrons

11.5.2.    Nuclear Reactors

11.6.    Asia Pacific Nuclear Medicine Market, By End User

11.6.1.    Hospitals

11.6.2.    Diagnostic Imaging Centers

11.6.3.    Ambulatory Surgical Centers

11.6.4.    Cancer Research Institute 

11.7.    Asia Pacific Nuclear Medicine Market Attractiveness Index

11.7.1.    By Country

11.7.2.    By Application

11.7.3.    By Radioisotope

11.7.4.    By Source

11.7.5.    By End User

12.    Middle East Nuclear Medicine Market, By Region

12.1.    Introduction

12.1.1.    Annual Growth Rate Comparison, By Country

12.1.2.    BPS Analysis, By Country

12.2.    Market (US$Mn) Forecast, By Country

12.2.1.    GCC Countries Nuclear Medicine Market

12.2.2.    Israel Nuclear Medicine Market

12.2.3.    Oman Nuclear Medicine Market

12.2.4.    Rest of Middle East Nuclear Medicine Market

12.3.    Middle East Nuclear Medicine Market, By Application

12.3.1.    Oncology

12.3.2.    Cardiology

12.3.3.    Gastroenterology

12.3.4.    Neuroendocrinology

12.3.5.    Neurology

12.3.6.    Nephrology

12.3.7.    Others

12.4.    Middle East Nuclear Medicine Market, By Radioisotope

12.4.1.    Tec. 99

12.4.2.    F18

12.4.3.    Iodine 131

12.4.4.    Lutetium 177

12.4.5.    Yttrium 90

12.4.6.    Gallium 68

12.4.7.    Gallium 67

12.4.8.    Rubidium 82

12.4.9.    Iodine 123

12.4.10.    Iodine 125

12.4.11.    Indium 111

12.4.12.    Others 

12.5.    Middle East Nuclear Medicine Market, By Source

12.5.1.    Cyclotrons

12.5.2.   Nuclear Reactors

12.6.    Middle East Nuclear Medicine Market, By End User

12.6.1.    Hospitals

12.6.2.    Diagnostic Imaging Centers

12.6.3.    Ambulatory Surgical Centers

12.6.4.    Cancer Research Institute 

12.7.    Middle East Nuclear Medicine Market Attractiveness Index

12.7.1.    By Country

12.7.2.    By Application

12.7.3.    By Radioisotope

12.7.4.    By Source

12.7.5.    By End User

13.    Africa Nuclear Medicine Market, By Region

13.1.    Introduction

13.1.1.    Annual Growth Rate Comparison, By Country

13.1.2.    BPS Analysis, By Country

13.2.    Market (US$Mn) Forecast, By Country

13.2.1.    South Africa Nuclear Medicine Market

13.2.2.    Egypt Nuclear Medicine Market

13.2.3.    North Africa Nuclear Medicine Market

13.2.4.    Rest of Africa Nuclear Medicine Market

13.3.    Africa Nuclear Medicine Market, By Application

13.3.1.    Oncology

13.3.2.    Cardiology

13.3.3.    Gastroenterology

13.3.4.    Neuroendocrinology

13.3.5.    Neurology

13.3.6.    Nephrology

13.3.7.    Others

13.4.    Africa Nuclear Medicine Market, By Radioisotope

13.4.1.    Tec. 99

13.4.2.    F18

13.4.3.    Iodine 131

13.4.4.    Lutetium 177

13.4.5.    Yttrium 90

13.4.6.    Gallium 68

13.4.7.    Gallium 67

13.4.8.    Rubidium 82

13.4.9.    Iodine 123

13.4.10.    Iodine 125

13.4.11.    Indium 111

13.4.12.    Others 

13.5.    Africa Nuclear Medicine Market, By Source

13.5.1.    Cyclotrons

13.5.2.    Nuclear Reactors

13.6.    Africa Nuclear Medicine Market, By End User

13.6.1.    Hospitals

13.6.2.    Diagnostic Imaging Centers

13.6.3.    Ambulatory Surgical Centers

13.6.4.    Cancer Research Institute 

13.7.    Africa Nuclear Medicine Market Attractiveness Index

13.7.1.    By Country

13.7.2.    By Application

13.7.3.    By Radioisotope

13.7.4.    By Source

13.7.5.    By End User

14.    Recommendation

14.1.    Market Strategy

15.    Competitive Landscape

15.1.    Competition Dashboard

15.2.    List and Company Overview of Global Key Players

15.3.    Company Profiles

15.3.1.    Siemens AG

15.3.1.1.    Company Overview

15.3.1.2.    Financial Overview

15.3.1.3.    Product Portfolio

15.3.1.4.    Key Developments

15.3.1.5.    Business Strategies

15.3.2.    Eckert & Ziegler

15.3.3.    Lantheus Holdings, Inc.

15.3.4.    Cardinal Health

15.3.5.    Bayer AG

15.3.6.    Bracco Imaging S.P.A.

15.3.7.    Nordian Inc.

15.3.8.    Advanced Accelerator Applications

15.3.9.    Mallinckrodt plc

16.    Acronyms

Select License Type

Frequently Asked Questions

The global nuclear medicine market in 2020 is estimated for more than US$ 4.3 Bn and expected to reach a value of US$ 6.3 Bn by 2028 with a significant CAGR of 4.8%.

Evolution towards centralized pharmacies, widespread availability of the SPECT and PET scanning machines, the growing interest of investors of conventional pharmaceutical industries in the therapeutic area, increasing incidence of cancer and cardiovascular diseases are some of the factors that will drive the growth of the nuclear medicine market

The global nuclear medicine market is segmented on the basis of application, radioisotope, source, end user, and by region

Siemens AG, Eckert & Ziegler, Lantheus Holdings, Inc., Cardinal Health, Bayer AG, Bracco Imaging S.P.A., Nordian Inc., Advanced Accelerator Applications, Mallinckrodt plc are the key participating players in the market